Home/Pipeline/BIIB122/DNL151

BIIB122/DNL151

Parkinson's disease

Phase 3Active

Key Facts

Indication

Parkinson's disease

Phase

Phase 3

Status

Active

Company

Denali Therapeutics

About Denali Therapeutics

Denali Therapeutics is on a mission to defeat neurodegeneration by creating medicines that cross biological barriers, particularly the blood-brain barrier. Founded in 2015, the company has established its proprietary TransportVehicle™ (TV) platform as a core competitive moat, enabling the delivery of therapeutic antibodies, enzymes, and other biologics into the central nervous system. Its strategy leverages this platform to build a broad pipeline targeting diseases like Parkinson's, Alzheimer's, ALS, and lysosomal storage disorders, with key programs advancing through mid- to late-stage clinical trials. Denali has secured major partnerships with industry leaders like Biogen and Takeda, validating its approach and providing non-dilutive capital to fuel its ambitious R&D agenda.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Lysosomal Storage Disorders

Other Parkinson's disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active